“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...

Disitamab vedotin plus toripalimab demonstrated a 63.6% pathologic complete response rate in HER2-expressing MIBC patients. The 12-month event-free survival rate was 92.5%, indicating promising ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

Avelumab plus BSC significantly prolongs OS and PFS in advanced urothelial carcinoma, regardless of diabetes mellitus status. The study included 700 patients, with a balanced distribution of diabetes ...

"I think this is the next step for testing the clinical activity of this agent," says David A. Braun, MD, PhD. In this video, David A. Braun, MD, PhD, describes background and design of the phase 2 ...

"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD. In this video, Gopa Iyer, MD, shares findings from an ...

ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2. Durable antitumor activity continued to be seen with combination treatment with belzutifan (Welireg) plus ...

“These data reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer," says Thomas Powles, MD, PhD. Additional follow-up data from the phase 3 EV-302 ...

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...

"The efficacy findings reported to date are 71% any time response," says John A. Taylor III, MD, MS. In this video, John A. Taylor III, MD, MS, shares the design and preliminary findings of the phase ...